ArticleJournal of bone and mineral metabolism2009
1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression.
Article in Journal of bone and mineral metabolism, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 60 citations in OpenAlex.
- Comparison the impact of IFN-β alone or in combination with vitamin D on critical pathways involved in AML progression.PloS one · 2025Article
- The role of magnesium in the pathogenesis of osteoporosis.Frontiers in endocrinology · 2024Review
- Effects of Hyperlipidemia on Osseointegration of Dental Implants and Its Strategies.Journal of functional biomaterials · 2023Review
- Osteonecrosis development by tooth extraction in zoledronate treated mice is inhibited by active vitamin D analogues, anti-inflammatory agents or antibiotics.Scientific reports · 2022Article
- Galectin-3 Contributes to the Inhibitory Effect of lα,25-(OH)International journal of molecular sciences · 2021Article
- Vitamin K and D Supplementation and Bone Health in Chronic Kidney Disease-Apart or Together?Nutrients · 2021Review
- Review
- Association of Anabolic Effect of Calcitriol with Osteoclast-Derived Wnt 10b Secretion.Nutrients · 2018Article
- The Effect of Inhalant Organic Dust on Bone Health.Current allergy and asthma reports · 2018Review
- An Optimized Method to Generate Human Active Osteoclasts From Peripheral Blood Monocytes.Frontiers in immunology · 2018Article
- Pharmacologic Calcitriol Inhibits Osteoclast Lineage Commitment via the BMP-Smad1 and IκB-NF-κB Pathways.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2017Article
- Histochemical examination of the effects of high-dose 1,25(OH)2D3 on bone remodeling in young growing rats.Journal of molecular histology · 2016Article
- Roles of the kidney in the formation, remodeling and repair of bone.Journal of nephrology · 2016Review
- Vitamin D receptor expression in human bone tissue and dose-dependent activation in resorbing osteoclasts.Bone research · 2016Article
- Effects of eldecalcitol on cortical bone response to mechanical loading in rats.BMC musculoskeletal disorders · 2015Article
- Vitamin D supplementation protects against bone loss following inhalant organic dust and lipopolysaccharide exposures in mice.Immunologic research · 2015Article
- Vitamin D endocrine system and osteoclasts.BoneKEy reports · 2014Article
- The vitamin D analogue ED71 but Not 1,25(OH)2D3 targets HIF1α protein in osteoclasts.PloS one · 2014Article
- Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclasts.Biochemia medica · 2013Review
- Retinoic acid inhibits NFATc1 expression and osteoclast differentiation.Journal of bone and mineral metabolism · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1-Alpha, 25-dihydroxy vitamin D(3) (1alpha,25(OH)(2)D(3)), an active form of vitamin D(3), plays a critical role in calcium and bone metabolism. Although 1alpha,25(OH)(2)D(3) has been used for osteoporosis therapy, the direct role of 1alpha,25(OH)(2)D(3) on human osteoclastogenesis has not been well characterized. Here we show that 1alpha,25(OH)(2)D(3) treatment significantly inhibited human osteoclast formation at the early stage of differentiation in a concentration-dependent manner. 1alpha,25(OH)(2)D(3) inhibited the expression of nuclear factor of activated T cells c1 (NFATc1, also referred as NFAT2), an essential transcription factor for osteoclast differentiation, and upregulated the expression of interferon-beta (IFN-beta), a strong inhibitor of osteoclastogenesis in osteoclast progenitors. Inhibitory effects of 1alpha,25(OH)(2)D(3) on osteoclastogenesis and NFATc1 expression were restored by treatment with an antibody against IFN-beta, suggesting that upregulation of IFN-beta by 1alpha,25(OH)(2)D(3) treatment results in inhibition of NFATc1 expression, in turn interfering with osteoclast formation. Thus, our study may provide a molecular basis for the treatment of human bone diseases by 1alpha,25(OH)(2)D(3) through regulation of the IFN-beta and NFATc1 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.